← All trials
NCT04829123
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 29, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Apr 2, 2021
- Last posted
- Aug 30, 2021
- Enrollment
- 100
- Arms / groups
- 11 / —
- Source
- AACT · ingestion pipeline
Sponsors
- TaiGen Biotechnology Co., Ltd.Lead sponsor
- Scientia Clinical Research Limited SydneyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.